The various vacancies against the Covid 19 without hesitation will help to end the pandemic, but it will continue to affect the major pharmaceutical companies.
The Pfizer (PFE) transnational agency, for example, is raising $ 20 dollars per dose, hoping that the sales of the vacant lot with the German BioNTech (BNTX) will reach $ 15,000 million for this year’s fines. , with a margin of over 30%, agreed with a CNN report.
For the company that will actually benefit the most from the vaccine against Covid es Moderna (MRN), a pharmaceutical company also known as Stadounidense, which is relatively new and has no products approved for sale until 2019. It is only $ 60 million in dollars. , received $ 529 million in subsidies and $ 200 million from the first sales of its homes in 2020.
The prognosis for ingress for 2021 is $ 16,000 million, in its mayor for the sale of vacancies. The actions of Moderna will be 187% in the last 12 months.
No benefits during the pandemic, pero …
The third vacancy approved in United States, Johnson & Johnson (JNJ), is the only one dose and has an effect a little lower than the previous ones, of 85%. The pharmaceutical company has said that the vaccine will increase its fines while the world continues to suffer from the pandemic, but this does not mean that the company will ever make money with it.
It is hoped that including the passage of the pandemic, the necessary persons will receive injections to protect the new varieties.
“There is one scenario that is most likely to be necessary in the coming years to reform the patients vaccinated with COVID-19 with a vaccine codifying the pico variant”, said Pfizer’s CEO Albert Bourla, in his called most recent analysts.
Además, Johnson & Johnson also benefited from the increase in its stock market share, as did Moderna and Pfizer. It is important to note that the only one that has not received a federal grant from the United States government to produce the Pfizer fleet, which corrects all costs.
Some problems and a phrase
The problems that have plagued AstraZeneca (AZN), the vacancy developed by the company of the same name and the University of Oxford, also need to benefit from the pharmaceutical companies. The majority of European countries have approved this vacancy and issued it as the primary source of communications against Covid, recently in Denmark, Iceland and Norway, and some in Germany, France and Italy, suspended their use of song reports in the evacuated persons.
The major EU transnational pharmaceutical company, Merck (MRK), stated its intention to release the vaccine, and discreetly entered into an agreement with Johnson & Johnson to respond to its production.
In general, vacancies are not lucrative for biopharmaceuticals.
“Influenza vaccines are a minor margin deal,” CNN analyst Seamus Fernández, senior executive director of Guggenheim Securities, told the Associated Press. Among the exceptions, without embarrassment, is the Prevnar vaccine, which protects the antiquities of the neo-moccasin, “extremely lucrative” for Pfizer. Its cost in the United States is more than $ 100 per dose, although some will cost without medical care.
A premium and image casi incalculable
More recently, the vacancies against the Covid train an important benefit extra for the biopharmaceuticals that the producers: the brand recognition.
“Really have a radical change in the form in which the people perceive,” said Tinglong Dai, professor of business at Johns Hopkins University. “Not his codic pharmaceutical companies that cobra scandals are expensive. They are salvaged all over the world. His public relations are really brilliant”.
Hecho, the media to reduce the prices of drugs in the United States, which are on the Trump administration’s agenda and will never be concreted, will not be mentioned by now.
Also you can be interested:
VIDEO | Why are there 5 myths about the vacidas of covid son falsos